Compounds and methods for the treatment of Alzheimer's disease and/or cerebral amyloid angiopathy
View Patent ↗Described herein are novel compounds and methods for the treatment and/or prevention of cerebral amyloidoses such as Alzheimer's disease (AD) and/or cerebral amyloid angiopathy (CAA).
1. A compound having a structure represented by formula II or IIA:
wherein: R 1 , R 3 , R 4 are independently chosen from H, C 1 -C 8 alkyl, aryl, (CH 2 ) n aryl, (CH 2 ) n heteroaryl;
n=0-8;
X=CO, SO, SO 2 , —CONH—, SO 2 NH—, SONH—;
Y=O, S, NH; and
A 1 , A 2 , B 1 , B 2 , C 1 , C 2 are independently chosen from H, OR 4 , F,
or a pharmaceutically acceptable salt, solvate, or prodrug thereof.
2. The compound of claim 1 , wherein R 4 is H.
3. The compound of claim 1 , wherein R 4 is benzyl.
4. The compound of claim 1 , wherein the compound has the following structure:
or a pharmaceutically acceptable salt, solvate, or prodrug thereof.
5. A pharmaceutical composition comprising:
a. the compound of claim 1 ; and
b. at least one pharmaceutically acceptable carrier.
6. A method for treating Alzheimer's disease and/or cerebral amyloid angiopathy in a patient at risk for developing or diagnosed with the same, the method comprising administering to the patient an effective amount of the compound of claim 1 .
7. The method of claim 6 , wherein the administration of an effective amount of the compound increases processing of one or more gangliosides selected from GM2 and GA2.
8. A method for enhancing the activity of β-hexosaminidase, the method comprising administering an effective amount of the compound of claim 1 .
9. A kit comprising:
a. the compound of claim 1 ; and
b. instructing for using the same to treat Alzheimer's disease and/or cerebral amyloid angiopathy.
10. A compound selected from the group consisting of:
or a pharmaceutically acceptable salt, solvate, or prodrug thereof.
11. A pharmaceutical composition comprising:
a. the compound of claim 10 ; and
b. at least one pharmaceutically acceptable carrier.
12. A method for treating Alzheimer's disease and/or cerebral amyloid angiopathy in a patient at risk for developing or diagnosed with the same, the method comprising administering to the patient an effective amount of the compound of claim 10 .
13. The method of claim 12 , wherein the administration of an effective amount of the compound increases processing of one or more gangliosides selected from GM2 and GA2.
14. A method for enhancing the activity of β-hexosaminidase, the method comprising administering an effective amount of the compound of claim 10 .
15. A kit comprising:
a. the compound of claim 10 ; and
b. instructing for using the same to treat Alzheimer's disease and/or cerebral amyloid angiopathy.